Compliance & Medical Disclaimer

This article is for informational and educational purposes only and does not constitute medical, legal, regulatory, or professional advice. The compounds discussed are research chemicals not approved for human consumption by the US FDA, European Medicines Agency (EMA), UK MHRA, Australian TGA, Health Canada, or any other major regulatory authority. They are sold strictly for laboratory research use. WolveStack does not employ medical staff, does not diagnose, treat, or prescribe, and makes no health claims under FTC, UK ASA, EU MDR/UCPD, or AU TGA standards. Always consult a licensed healthcare professional in your jurisdiction before considering any peptide protocol. This site contains affiliate links (FTC 2023 endorsement guidelines compliant); we may earn a commission on qualifying purchases at no additional cost to you. Some compounds discussed are on the WADA prohibited list — competitive athletes should verify current status with their governing body before any research use. Use of research chemicals may be illegal in your jurisdiction.

Reviewed by: WolveStack Research Team
Last reviewed: 2026-04-28
Editorial policy

Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.

Medical Disclaimer

For informational and educational purposes only. Not FDA-approved for human use. Consult a licensed healthcare professional. See full disclaimer.

AOD-9604 and 5-Amino-1MQ operate through different mechanisms: AOD-9604 directly stimulates fat breakdown, while 5-Amino-1MQ shifts metabolism away from fat storage. For solo use, AOD-9604 has stronger clinical evidence (Phase 2 trials); 5-Amino-1MQ shows promise in animal studies but lacks human data. Stacked together, they're synergistic—most experts recommend combining both for optimal results.

AOD-9604 vs. 5-Amino-1MQ: Core Differences

These peptides are often compared because both target fat loss, but they accomplish this through fundamentally different pathways. Understanding the distinction helps you choose which one (or both) best suits your goals.

Mechanism of Action: The Key Difference

AOD-9604: Direct Lipolysis

AOD-9604 binds to growth hormone receptors on fat cells and activates hormone-sensitive lipase (HSL), directly triggering fat breakdown. It's a "push" approach—you're actively telling fat cells to release their stored energy.

5-Amino-1MQ: Metabolic Shift

5-Amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that regulates metabolism direction. By blocking NNMT, the peptide shifts your body's fuel preference toward fat oxidation and away from storage. It's a "pull" approach—you're reorienting metabolism to burn fat preferentially.

Visual Comparison:

Aspect AOD-9604 5-Amino-1MQ
Primary mechanism Lipolysis (fat breakdown) NNMT inhibition (metabolic shift)
Target receptor hGH receptor NNMT enzyme
Action on fat Actively breaks down stored fat Prevents new fat storage, favors burning
Timeline Immediate lipolytic effect Gradual metabolic shift over weeks

Clinical Evidence Comparison

AOD-9604: Established Evidence

5-Amino-1MQ: Emerging Evidence

Verdict: AOD-9604 has stronger human evidence; 5-Amino-1MQ has more exciting animal data. For risk-averse researchers, AOD-9604 is the safer solo choice. For innovation seekers, 5-Amino-1MQ is compelling but unproven in humans.

Expected Results: Solo Use

AOD-9604 Alone (12 Weeks):

5-Amino-1MQ Alone (12 Weeks):

Honest Assessment: Community reports suggest 5-Amino-1MQ may outperform AOD-9604 in practice, but individual variation is high. Some users report 10–15kg loss; others see 2–3kg. AOD-9604 results are more predictable because they're anchored in clinical data.

Side Effects: AOD-9604 vs. 5-Amino-1MQ

AOD-9604 Side Effects:

5-Amino-1MQ Side Effects:

Verdict: AOD-9604 has proven excellent tolerability. 5-Amino-1MQ is theoretically safe but less documented in humans. If side effects concern you, AOD-9604 is the safer choice.

Cost-Effectiveness Comparison

Factor AOD-9604 5-Amino-1MQ
Typical cost (12 weeks) $250–400 $150–300
Expected fat loss 4–8kg 6–12kg (unproven)
Cost per kg (worst case) $50/kg $25/kg
Cost per kg (best case) $31/kg $12/kg
Confidence in results High (clinical data) Medium (animal data)

Cost Winner: 5-Amino-1MQ is cheaper and potentially more potent (cost per kg better). But AOD-9604 offers more certainty—you know what you're getting based on human evidence.

Which Should You Choose? Decision Framework

Choose AOD-9604 If:

Choose 5-Amino-1MQ If:

Stack Both If:

Can You Combine Them? Synergy Analysis

Mechanism Compatibility:

Yes, AOD-9604 + 5-Amino-1MQ are highly synergistic. AOD-9604 mobilizes fat (push); 5-Amino-1MQ prevents new storage and favors oxidation (pull). Combined, they work through different pathways, creating complementary effects.

Expected Synergistic Results:

Community reports show 50–100% improvement when stacked versus solo use:

This synergistic multiplier makes stacking the most cost-effective approach for ambitious fat-loss goals.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Particle Peptides

Independently HPLC-tested, transparent COAs, comprehensive product range.

Browse Particle Peptides →

Limitless Life Nootropics

Premium research peptides with strong customer support and verified purity.

Browse Limitless Life →

FAQ: AOD-9604 vs. 5-Amino-1MQ

Which is more potent: AOD-9604 or 5-Amino-1MQ?

Unknown in humans. Animal data favors 5-Amino-1MQ (stronger weight-loss effects), but human trials don't exist. Clinical evidence favors AOD-9604 (proven in 900+ subjects). Best assumption: they're similar in potency; 5-Amino-1MQ may have edge if animal data translates.

Is 5-Amino-1MQ safer than AOD-9604?

AOD-9604 has proven safety (Phase 2 trials). 5-Amino-1MQ is theoretically safe (animal studies, no serious adverse effects) but unproven in humans. AOD-9604 is the safer choice due to documented human evidence. 5-Amino-1MQ is safe on paper but lacks real-world human data.

Should I start with one and add the other later?

Yes, smart approach. Start with AOD-9604 alone for 4–6 weeks to establish baseline tolerance. Once comfortable, add 5-Amino-1MQ. This allows you to attribute results/side effects to each compound. If you start both together, you won't know which is driving results or side effects.

Can 5-Amino-1MQ replace AOD-9604?

Theoretically yes (if it's as potent as animal data suggest), but not with confidence. AOD-9604 is proven; 5-Amino-1MQ is promising. If budget is tight, start with 5-Amino-1MQ for cost savings, but accept higher uncertainty. If certain results matter, start with AOD-9604.

Why isn't 5-Amino-1MQ in human trials yet if it's so promising?

No company has invested in Phase 1 human trials. Reasons: (1) Patent/IP complexity, (2) expensive development pathway, (3) 5-Amino-1MQ is newer than AOD-9604. As interest grows, human trials may eventually happen, but for now, it remains a research peptide with animal evidence only.

What if 5-Amino-1MQ doesn't work for me?

Variable human response is expected (animal data doesn't always translate). If you try 5-Amino-1MQ alone for 8 weeks with diet/training discipline and see minimal results, switch to AOD-9604 or combine both. Don't waste time on ineffective protocols; pivot quickly based on results.

Home Start Here Calculator Vendors About Disclosure Privacy Terms

© 2026 WolveStack. For research and educational purposes only.

WolveStack publishes research summaries for educational purposes only. Nothing here constitutes medical advice. All peptides discussed are for research use only. Consult a qualified healthcare professional before use.